Skip to content

Study · Randomized controlled trial · n = 58 · 2024

6 results

Intranasal oxytocin as an adjunct treatment among patients with severe major depression with and without comorbid borderline personality disorder.

Maoz H, Grossman-Giron A, Sedoff O, Nitzan U, Kashua H, Yarmishin M, Arad O, Tzur Bitan D

Journal of affective disorders20 Nov 2023Cited by 12 (Europe PMC)

PMID37992767 (opens in a new tab)DOI10.1016/j.jad.2023.11.053 (opens in a new tab)PepBankPUB-37992767
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with severe major depression, the effect of intranasal oxytocin on the Outcome Questionnaire-45 differed by comorbid borderline personality disorder.

    In plain wordsIn patients with severe depression, the effect of nasal oxytocin on symptom scores depended on whether they also had borderline personality disorder.

    Peptide
    Oxytocin
    Outcome
    MixedOutcome Questionnaire-45, diagnosis by group interaction
    Study

    n = 58

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    32 IU twice daily · intranasal · four weeksAs given in this study (human).

    Source sentences

    Summary
    An interaction effect between diagnosis and group was observed on the Outcome Questionnaire-45 (B = 8.93, p = .007).
    2 context sentences
    Summary · context
    Patients treated in inpatient settings (N = 58) were randomized and double-blindly allocated to receive twice daily IN-OT (32 IU) or placebo for a period of four weeks.
    Summary · context
    The effect of IN-OT on therapy process and outcome was examined among patients with (n = 35) and without (n = 23) comorbid BPD.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with major depression and comorbid borderline personality disorder, intranasal oxytocin did not significantly improve Outcome Questionnaire-45 scores.

    In plain wordsIn patients with depression and borderline personality disorder, nasal oxytocin did not significantly improve symptom scores.

    Peptide
    Oxytocin
    Outcome
    No significant changeOutcome Questionnaire-45 in patients with BPD
    Study

    n = 35

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    32 IU twice daily · intranasal · four weeksAs given in this study (human).

    Source sentences

    Summary
    Further analysis revealed that patients without BPD demonstrated significantly greater improvements following OT administration (B = -8.32, p = .001), whereas patients with BPD did not show significant improvement (B = 0.61, p = .76).
    2 context sentences
    Summary · context
    Patients treated in inpatient settings (N = 58) were randomized and double-blindly allocated to receive twice daily IN-OT (32 IU) or placebo for a period of four weeks.
    Summary · context
    The effect of IN-OT on therapy process and outcome was examined among patients with (n = 35) and without (n = 23) comorbid BPD.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with major depression and comorbid borderline personality disorder, intranasal oxytocin gave no significant improvement on the Hopkins Symptom Checklist.

    In plain wordsIn patients with depression and borderline personality disorder, nasal oxytocin gave no significant symptom improvement.

    Peptide
    Oxytocin
    Outcome
    No significant changeHopkins Symptom Checklist in patients with BPD
    Study

    n = 35

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    32 IU twice daily · intranasal · four weeksAs given in this study (human).

    Source sentences

    Summary
    The interactive pattern was also observed in the Hopkins Symptom Checklist (B = 0.25, p = .02), where patients without BPD demonstrated significantly larger improvements following OT administration (B = -0.29, p = .0009) as compared to placebo, while patients with BPD demonstrated no significant imp…
    2 context sentences
    Summary · context
    Patients treated in inpatient settings (N = 58) were randomized and double-blindly allocated to receive twice daily IN-OT (32 IU) or placebo for a period of four weeks.
    Summary · context
    The effect of IN-OT on therapy process and outcome was examined among patients with (n = 35) and without (n = 23) comorbid BPD.
  4. 04HumanRandomized controlled trialSafety outcome

    In patients with major depression and comorbid borderline personality disorder, no harmful effect of intranasal oxytocin was found.

    In plain wordsIn patients with depression and borderline personality disorder, no harmful effect of nasal oxytocin was found.

    Peptide
    Oxytocin
    Outcome
    No significant changeHarmful effect in patients with MDD and BPD
    Study

    n = 35

    Comparator
    Placebo
    Outcome group
    Adverse events · Mental health and mood
    Studied dose
    32 IU twice daily · intranasal · four weeksAs given in this study (human).

    Source sentences

    Summary
    We did not find a harmful effect of IN-OT administration among patients with MDD and comorbid BPD.
    2 context sentences
    Summary · context
    Patients treated in inpatient settings (N = 58) were randomized and double-blindly allocated to receive twice daily IN-OT (32 IU) or placebo for a period of four weeks.
    Summary · context
    The effect of IN-OT on therapy process and outcome was examined among patients with (n = 35) and without (n = 23) comorbid BPD.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with major depression without comorbid borderline personality disorder, intranasal oxytocin significantly improved Outcome Questionnaire-45 scores.

    In plain wordsIn patients with depression but no borderline personality disorder, nasal oxytocin improved symptom scores.

    Peptide
    Oxytocin
    Outcome
    DecreaseOutcome Questionnaire-45 in patients without BPD
    Study

    n = 23

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    32 IU twice daily · intranasal · four weeksAs given in this study (human).

    Source sentences

    Summary
    Further analysis revealed that patients without BPD demonstrated significantly greater improvements following OT administration (B = -8.32, p = .001), whereas patients with BPD did not show significant improvement (B = 0.61, p = .76).
    2 context sentences
    Summary · context
    Patients treated in inpatient settings (N = 58) were randomized and double-blindly allocated to receive twice daily IN-OT (32 IU) or placebo for a period of four weeks.
    Summary · context
    The effect of IN-OT on therapy process and outcome was examined among patients with (n = 35) and without (n = 23) comorbid BPD.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with major depression without comorbid borderline personality disorder, intranasal oxytocin gave larger improvements on the Hopkins Symptom Checklist than placebo.

    In plain wordsIn patients with depression but no borderline personality disorder, nasal oxytocin improved symptoms more than placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseHopkins Symptom Checklist in patients without BPD
    Study

    n = 23

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    32 IU twice daily · intranasal · four weeksAs given in this study (human).

    Source sentences

    Summary
    The interactive pattern was also observed in the Hopkins Symptom Checklist (B = 0.25, p = .02), where patients without BPD demonstrated significantly larger improvements following OT administration (B = -0.29, p = .0009) as compared to placebo, while patients with BPD demonstrated no significant imp…
    2 context sentences
    Summary · context
    Patients treated in inpatient settings (N = 58) were randomized and double-blindly allocated to receive twice daily IN-OT (32 IU) or placebo for a period of four weeks.
    Summary · context
    The effect of IN-OT on therapy process and outcome was examined among patients with (n = 35) and without (n = 23) comorbid BPD.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.